Regulatory

Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology

May 22nd 2022

By Skylar Jeremias

The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.

Dr Eric Tichy Calls for Government Officials to Realign Incentives in Favor of Biosimilars

May 18th 2022

By Skylar Jeremias

Video

Altering reimbursement procedures needs to become a bigger priority for government officials to incentivize biosimilar utilization, according to Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System.

Teva’s Lucentis Biosimilar Gains UK Approval

May 17th 2022

By Skylar Jeremias

Article

The United Kingdom has approved Teva Pharmaceutical’s biosimilar (Ongavia) that references Lucentis (ranibizumab) for the treatment of several ophthalmic conditions.

Julie Reed Talks About How Savings Can Differ Between Patients, Health Plans

May 14th 2022

By Skylar Jeremias

Video

Julie M. Reed, the executive director of the Biosimilars Forum, discusses how biosimilar savings can differ between stakeholders and the importance of competition for creating those savings.

New House Bill Could Expand User Fee Programs for Biosimilars

May 12th 2022

By Skylar Jeremias

Article

A new bill that would amend the Federal Food, Drug, and Cosmetic Act aims to expand FDA user fee programs for prescription drugs and medical devices, including biosimilars and generics.

Medicare Policies Must Fix Cost Sharing Under Part D, Expert Writes

May 4th 2022

By Mary Caffrey

Article

Stacie B. Dusetzina, PhD, is the Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center, and a member of the editorial board for The American Journal of Managed Care®.

Julie Reed: House Hearing Omitted Biosimilar Issues Despite Growing Need for Solutions

May 4th 2022

By Skylar Jeremias

Video

The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.

The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei

May 3rd 2022

By Laura Joszt

Article

The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.

Dr Eric Tichy Details Why More State Biosimilar Bills Are Needed

May 1st 2022

By Skylar Jeremias

Video

Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, discusses the importance of state legislation to boost biosimilar access and uptake.

Dr Sarfaraz K. Niazi Claims Biosimilar Growth Signals Need for Greater Testing, Policy Reform

April 28th 2022

By Skylar Jeremias

Article

Now that the United States’ acceptance of biosimilars matches that in the European Union, developers should be encouraging changes to testing regulations to increase biosimilar accessibility, according to Sarfaraz K. Niazi, PhD, in his recent perspective paper.